Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV)

Slides:

Advertisements

Similar presentations

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response

Advertisements

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Schematic representation of the experimental design.

Figure 1 Mechanism of mortality benefit associated with radial access

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Figure 1 Phases of the research. Author’s own work.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Structure of two poxtA-carrying plasmids in E

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

AHA: American Heart Association; ALT: ...

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1. SpeI-PFGE dendrogram comparing P

Source: Figure created by the author based on data ...

bDMARD: biologic DMARD.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Figure 1. Historical dialectic framework to assess transnational advocacy network influence Unless provided in the caption above, the following copyright.

Take home figure The protective role of CNP/NPR-B/NPRC.

Fig. 3 Interrelationship between themes describing the experiences of people with shoulder disorders Unless provided in the caption above, the following.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

x-axis, post-partum days. Closed ...

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Figure 1. Mean log10 cfu/mL versus time profile for each individual drug at 4× MIC against the four VRE ... Figure 1. Mean log10 cfu/mL versus.

Fig. 1 Flow chart for selection of study subjects

Figure 1. Susceptibility of all P

Figure 1. (a) Geographical representation of sample collection area

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

Figure 1. Flow diagram for selection of articles for systematic review. Unless provided in the caption above, the following copyright applies to the content.

Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Figure 1 MIC test strips showing reversion of daptomycin resistance of isolate 5 passaged in vitro. This figure ... Figure 1 MIC test strips showing reversion.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1. Observed mean (SD) micafungin plasma concentrations.

Figure 1. Time–kill curves of M. abscessus CIP

Fig. 1 A network representation of top 100 co-occurring terms

Figure 1. Genetic context of blaNDM-21 on pNDM21_020023

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Statistics of the main characters’ dialogues.

Figure 1 Patient selection.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of.

Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and ... Figure 1. Percentage of samples with.

Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in ... Figure 1. CCG and practice decile.

Figure 1 Strategies for reconciling protection and participation.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1. Measuring respondent unhappiness with their child marrying someone from the other party and happiness with ... Figure 1. Measuring respondent.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Evolutionary process of a policy field.

Table 2. Mean noise level results for hand dryers in dBA

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Figure 1. Kaplan–Meier curves showing the impact of the different pretreatment HIV-1 drug resistance categories on the ... Figure 1. Kaplan–Meier curves.

Presentation transcript:

Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot samples at study entry (before starting ledipasvir/sofosbuvir), weeks 1, 2, 4 and 8 of ledipasvir/sofosbuvir treatment and 2, 4, 8 and 12 weeks after completing ledipasvir/sofosbuvir treatment (EOT + 2, EOT + 4, EOT + 8 and EOT + 12). Concentrations of tenofovir diphosphate during ledipasvir/sofosbuvir treatment were compared with entry using a paired t-test. (b) Geometric mean (%CV) tenofovir concentrations (TFV in ng/mL) in plasma samples at study entry (before starting ledipasvir/sofosbuvir), after 8 weeks of ledipasvir/sofosbuvir treatment and 12 weeks after completing ledipasvir/sofosbuvir treatment (EOT + 12). The tenofovir concentrations were 2.1-fold higher at week 8 versus study entry (P = 0.0005). GMR, geometric mean ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices) J Antimicrob Chemother, Volume 73, Issue 8, 09 May 2018, Pages 2112–2119, https://doi.org/10.1093/jac/dky146 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 1. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 1. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot samples at study entry (before starting sofosbuvir + ribavirin), after 12 weeks of sofosbuvir + ribavirin treatment and 12 weeks after completing sofosbuvir + ribavirin treatment (EOT + 12). Concentrations at week 12 of sofosbuvir + ribavirin treatment were compared with entry using a paired t-test. (b) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/million cells) in PBMC samples at study entry (before starting sofosbuvir + ribavirin), after 12 weeks of sofosbuvir + ribavirin treatment and 12 weeks after completing sofosbuvir + ribavirin treatment (EOT + 12). Concentrations at week 12 of sofosbuvir + ribavirin treatment were compared with entry using a paired t-test. (c) Geometric mean (%CV) tenofovir concentrations (TFV in ng/mL) in plasma samples at study entry (before starting sofosbuvir + ribavirin), after 12 weeks of sofosbuvir + ribavirin treatment and 12 weeks after completing sofosbuvir + ribavirin treatment (EOT + 12). The tenofovir concentrations were similar to historical data and unchanged across visits (P = 0.83). GMR, geometric mean ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices) J Antimicrob Chemother, Volume 73, Issue 8, 09 May 2018, Pages 2112–2119, https://doi.org/10.1093/jac/dky146 The content of this slide may be subject to copyright: please see the slide notes for details.